Dose Modifications News Today

Heather Moore, CPP, PharmD, highlights key contributions from pharmacists in breast cancer treatment and identifies current unmet needs in the treatment landscape.

Late-breaking data from DESTINY-Lung02 phase 2 trial of ENHERTU in patients with previously treated HER2 mutant metastatic non-small cell lung cancer to be featured Proffered paper presentation

Daiichi Sankyo and AstraZeneca's ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial evaluating the efficacy and safety of ENHERTU (trastuzumab

DESTINY-Breast03 data presented at SABCS 2021 showed Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a similar benefit in patient subgroups, including those with stable brain metastases, compared

Additional analyses of DESTINY-Breast03 trial of ENHERTU and updated results from triple negative breast cancer cohort of TROPION-PanTumor01 trial of datopotamab deruxtecan to be highlighted Daiichi

Daiichi Sankyo Company, Limited: Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer ii 80% (n=64) CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response i Includes patients with =1 postbaseline scan or who discontinued treatment. ii ORR is CR+PR; Responses are confirmed (CRs/PRs; n=32) plus those CRs/PRs to...

Daiichi Sankyo Company, Limited: ENHERTU Receives Prime Ministers Award from the Japan Techno-Economics Society Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC), received the Prime Ministers Award at the 9 th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). The Technology Management and Innovation Awards were established in 2012 with th...

Daiichi Sankyo Company, Limited: ENHERTU Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZenecas ENHERTU (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen...